| Objectives: To study the effects of acarbose on the intestinal flora and chronic inflammatory state in patients with type 2 diabetes.Methods: 23 type 2 diabetic patients were enrolled from inpatient department (complicated with metabolic syndrome), and divided randomly into 2 groups: one was given acarbose 50 mg three times a day, taken with meals for a period of 10 to 15 days. And the other not but other hypoglycemic treatments was the same (subcutaneous injection of insulin or orally taking hypoglycemic agents) as in group one. Samples of feces were collected and blood were withdrawn before and after treatment. Intestinal bifidobacterium was by determined with quantitative fluorescent PCR, MCP-1 and TNF-a were evaluated with ELISA. The relationship between flora changes of bifidobacterium in feces in diabetes and chronic inflammatory state and that of the effects of taking acarbose were analysed, Secondary aim is to analyze the relation of glycemia control with the change of inflammation status.Resuls:1. There were no significant differences in numbers of bifidobacterium between before and after acarbose treatment (P>0.05).2. No significant differences in MCP-1and TNF-αbetween acarbose group and control group were found.3. The values of MCP-1and TNF-αwere decreased between admission and the day of discharge, and was associated with glycemic control.Conclusions:1. No significant influence of acarbose usage on gastrointestinal flora and the inflammation status. The number of patients and duration of treatment might limit the results and its interpretation. The decrease in inflammation status does associate the glycemic control. Therefore, at present glycemic control, irrespective of its treatment modality, is still one of the goals in diabetic management.2. It is still to need further study the effect of acarbose treatment on gastrointestinal microbiota in larger scale and longer time setting. |
PDF Full Text Request